APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cancer Radioimmunotherapy

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Cancer Radioimmunotherapy Industry Growth and Trends Forecast to 2032

28 December 2025110 pages

Choose your research edition.

Industry ResearchCancer Radioimmunotherapy Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Radioimmunotherapy Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Cancer Radioimmunotherapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Radioimmunotherapy Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Radioimmunotherapy Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

According to APO Research, the global Cancer Radioimmunotherapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Cancer Radioimmunotherapy is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Cancer Radioimmunotherapy is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cancer Radioimmunotherapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Cancer Radioimmunotherapy market include Novartis, Bayer, Y-mAbs Therapeutics, Telix Pharmaceuticals, RadioMedix, Philogen, Orano Med, Nordic Nanovector and Mundipharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Cancer Radioimmunotherapy market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Cancer Radioimmunotherapy market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Cancer Radioimmunotherapy market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Cancer Radioimmunotherapy.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Cancer Radioimmunotherapy market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Cancer Radioimmunotherapy Market by Company

Novartis

Bayer

Y-mAbs Therapeutics

Telix Pharmaceuticals

RadioMedix

Philogen

Orano Med

Nordic Nanovector

Mundipharma

Lantheus

Gilead Sciences

Fusion Pharmaceuticals

Curium Pharmaceuticals

Curasight

Clarity Pharmaceuticals

China Isotope & Radiation

Aurobindo Pharma

Actinium Pharmaceuticals

Cancer Radioimmunotherapy Segment by Type

Beta-emitting

Targeted Alpha Therapy

Cancer Radioimmunotherapy Segment by Application

Solid Tumor

Non Hodgkin Lymphoma

Cancer Radioimmunotherapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Radioimmunotherapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Radioimmunotherapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Radioimmunotherapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Cancer Radioimmunotherapy companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Cancer Radioimmunotherapy Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Cancer Radioimmunotherapy Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Cancer Radioimmunotherapy Market Share by Region (2021-2026) Table 4. Global Cancer Radioimmunotherapy Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Cancer Radioimmunotherapy Market Share by Region (2027-2032) Table 6. Global Cancer Radioimmunotherapy Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Cancer Radioimmunotherapy Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Cancer Radioimmunotherapy Market Size Share by Type (2021-2026) Table 9. Global Cancer Radioimmunotherapy Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Cancer Radioimmunotherapy Market Size Share Forecasted by Type (2027-2032) Table 11. North America Cancer Radioimmunotherapy Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Cancer Radioimmunotherapy Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Cancer Radioimmunotherapy Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Cancer Radioimmunotherapy Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Cancer Radioimmunotherapy Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Cancer Radioimmunotherapy Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Cancer Radioimmunotherapy Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Cancer Radioimmunotherapy Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Cancer Radioimmunotherapy Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Cancer Radioimmunotherapy Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Cancer Radioimmunotherapy Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Cancer Radioimmunotherapy Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Cancer Radioimmunotherapy Market Size Share by Application (2021-2026) Table 24. Global Cancer Radioimmunotherapy Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Cancer Radioimmunotherapy Market Size Share Forecasted by Application (2027-2032) Table 26. North America Cancer Radioimmunotherapy Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Cancer Radioimmunotherapy Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Cancer Radioimmunotherapy Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Cancer Radioimmunotherapy Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Cancer Radioimmunotherapy Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Cancer Radioimmunotherapy Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Cancer Radioimmunotherapy Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Cancer Radioimmunotherapy Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Cancer Radioimmunotherapy Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Cancer Radioimmunotherapy Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Cancer Radioimmunotherapy Industry Trends Table 37. Cancer Radioimmunotherapy Industry Drivers Table 38. Cancer Radioimmunotherapy Industry Opportunities and Challenges Table 39. Cancer Radioimmunotherapy Industry Restraints Table 40. Global Cancer Radioimmunotherapy Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Cancer Radioimmunotherapy Revenue Market Share by Company (2021-2026) Table 42. Global Cancer Radioimmunotherapy Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Cancer Radioimmunotherapy Key Company Headquarters & Area Served Table 44. Global Cancer Radioimmunotherapy Company, Product Type & Application Table 45. Global Cancer Radioimmunotherapy Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Cancer Radioimmunotherapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Novartis Company Information Table 49. Novartis Business Overview Table 50. Novartis Cancer Radioimmunotherapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Novartis Cancer Radioimmunotherapy Product Portfolio Table 52. Novartis Recent Development Table 53. Bayer Company Information Table 54. Bayer Business Overview Table 55. Bayer Cancer Radioimmunotherapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Bayer Cancer Radioimmunotherapy Product Portfolio Table 57. Bayer Recent Development Table 58. Y-mAbs Therapeutics Company Information Table 59. Y-mAbs Therapeutics Business Overview Table 60. Y-mAbs Therapeutics Cancer Radioimmunotherapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Y-mAbs Therapeutics Cancer Radioimmunotherapy Product Portfolio Table 62. Y-mAbs Therapeutics Recent Development Table 63. Telix Pharmaceuticals Company Information Table 64. Telix Pharmaceuticals Business Overview Table 65. Telix Pharmaceuticals Cancer Radioimmunotherapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Telix Pharmaceuticals Cancer Radioimmunotherapy Product Portfolio Table 67. Telix Pharmaceuticals Recent Development Table 68. RadioMedix Company Information Table 69. RadioMedix Business Overview Table 70. RadioMedix Cancer Radioimmunotherapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. RadioMedix Cancer Radioimmunotherapy Product Portfolio Table 72. RadioMedix Recent Development Table 73. Philogen Company Information Table 74. Philogen Business Overview Table 75. Philogen Cancer Radioimmunotherapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Philogen Cancer Radioimmunotherapy Product Portfolio Table 77. Philogen Recent Development Table 78. Orano Med Company Information Table 79. Orano Med Business Overview Table 80. Orano Med Cancer Radioimmunotherapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Orano Med Cancer Radioimmunotherapy Product Portfolio Table 82. Orano Med Recent Development Table 83. Nordic Nanovector Company Information Table 84. Nordic Nanovector Business Overview Table 85. Nordic Nanovector Cancer Radioimmunotherapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Nordic Nanovector Cancer Radioimmunotherapy Product Portfolio Table 87. Nordic Nanovector Recent Development Table 88. Mundipharma Company Information Table 89. Mundipharma Business Overview Table 90. Mundipharma Cancer Radioimmunotherapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Mundipharma Cancer Radioimmunotherapy Product Portfolio Table 92. Mundipharma Recent Development Table 93. Lantheus Company Information Table 94. Lantheus Business Overview Table 95. Lantheus Cancer Radioimmunotherapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Lantheus Cancer Radioimmunotherapy Product Portfolio Table 97. Lantheus Recent Development Table 98. Gilead Sciences Company Information Table 99. Gilead Sciences Business Overview Table 100. Gilead Sciences Cancer Radioimmunotherapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Gilead Sciences Cancer Radioimmunotherapy Product Portfolio Table 102. Gilead Sciences Recent Development Table 103. Fusion Pharmaceuticals Company Information Table 104. Fusion Pharmaceuticals Business Overview Table 105. Fusion Pharmaceuticals Cancer Radioimmunotherapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Fusion Pharmaceuticals Cancer Radioimmunotherapy Product Portfolio Table 107. Fusion Pharmaceuticals Recent Development Table 108. Curium Pharmaceuticals Company Information Table 109. Curium Pharmaceuticals Business Overview Table 110. Curium Pharmaceuticals Cancer Radioimmunotherapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Curium Pharmaceuticals Cancer Radioimmunotherapy Product Portfolio Table 112. Curium Pharmaceuticals Recent Development Table 113. Curasight Company Information Table 114. Curasight Business Overview Table 115. Curasight Cancer Radioimmunotherapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Curasight Cancer Radioimmunotherapy Product Portfolio Table 117. Curasight Recent Development Table 118. Clarity Pharmaceuticals Company Information Table 119. Clarity Pharmaceuticals Business Overview Table 120. Clarity Pharmaceuticals Cancer Radioimmunotherapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. Clarity Pharmaceuticals Cancer Radioimmunotherapy Product Portfolio Table 122. Clarity Pharmaceuticals Recent Development Table 123. China Isotope & Radiation Company Information Table 124. China Isotope & Radiation Business Overview Table 125. China Isotope & Radiation Cancer Radioimmunotherapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. China Isotope & Radiation Cancer Radioimmunotherapy Product Portfolio Table 127. China Isotope & Radiation Recent Development Table 128. Aurobindo Pharma Company Information Table 129. Aurobindo Pharma Business Overview Table 130. Aurobindo Pharma Cancer Radioimmunotherapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. Aurobindo Pharma Cancer Radioimmunotherapy Product Portfolio Table 132. Aurobindo Pharma Recent Development Table 133. Actinium Pharmaceuticals Company Information Table 134. Actinium Pharmaceuticals Business Overview Table 135. Actinium Pharmaceuticals Cancer Radioimmunotherapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 136. Actinium Pharmaceuticals Cancer Radioimmunotherapy Product Portfolio Table 137. Actinium Pharmaceuticals Recent Development Table 138. North America Cancer Radioimmunotherapy Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. North America Cancer Radioimmunotherapy Market Size by Country (2021-2026) & (US$ Million) Table 140. North America Cancer Radioimmunotherapy Market Share by Country (2021-2026) Table 141. North America Cancer Radioimmunotherapy Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. North America Cancer Radioimmunotherapy Market Share Forecast by Country (2027-2032) Table 143. Europe Cancer Radioimmunotherapy Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. Europe Cancer Radioimmunotherapy Market Size by Country (2021-2026) & (US$ Million) Table 145. Europe Cancer Radioimmunotherapy Market Share by Country (2021-2026) Table 146. Europe Cancer Radioimmunotherapy Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. Europe Cancer Radioimmunotherapy Market Share Forecast by Country (2027-2032) Table 148. Asia-Pacific Cancer Radioimmunotherapy Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. Asia-Pacific Cancer Radioimmunotherapy Market Size by Country (2021-2026) & (US$ Million) Table 150. Asia-Pacific Cancer Radioimmunotherapy Market Share by Country (2021-2026) Table 151. Asia-Pacific Cancer Radioimmunotherapy Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. Asia-Pacific Cancer Radioimmunotherapy Market Share Forecast by Country (2027-2032) Table 153. Latin America Cancer Radioimmunotherapy Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. Latin America Cancer Radioimmunotherapy Market Size by Country (2021-2026) & (US$ Million) Table 155. Latin America Cancer Radioimmunotherapy Market Share by Country (2021-2026) Table 156. Latin America Cancer Radioimmunotherapy Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. Latin America Cancer Radioimmunotherapy Market Share Forecast by Country (2027-2032) Table 158. Middle East & Africa Cancer Radioimmunotherapy Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Middle East & Africa Cancer Radioimmunotherapy Market Size by Country (2021-2026) & (US$ Million) Table 160. Middle East & Africa Cancer Radioimmunotherapy Market Share by Country (2021-2026) Table 161. Middle East & Africa Cancer Radioimmunotherapy Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Middle East & Africa Cancer Radioimmunotherapy Market Share Forecast by Country (2027-2032) Table 163. Research Programs/Design for This Report Table 164. Authors List of This Report Table 165. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Cancer Radioimmunotherapy Product Image Figure 3. Global Cancer Radioimmunotherapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Cancer Radioimmunotherapy Market Size (2021-2032) & (US$ Million) Figure 5. Global Cancer Radioimmunotherapy Market Share by Region: 2025 VS 2032 Figure 6. Global Cancer Radioimmunotherapy Market Share by Region (2021-2032) Figure 7. North America Cancer Radioimmunotherapy Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Cancer Radioimmunotherapy Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Cancer Radioimmunotherapy Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Cancer Radioimmunotherapy Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Cancer Radioimmunotherapy Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Beta-emitting Image Figure 13. Global Beta-emitting Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Targeted Alpha Therapy Image Figure 15. Global Targeted Alpha Therapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Global Cancer Radioimmunotherapy Market Size Overview by Type (2021-2032) & (US$ Million) Figure 17. Global Cancer Radioimmunotherapy Market Share by Type 2025 VS 2032 Figure 18. North America Cancer Radioimmunotherapy Market Size Share by Type (2021-2032) Figure 19. Europe Cancer Radioimmunotherapy Market Size Share by Type (2021-2032) Figure 20. Asia-Pacific Cancer Radioimmunotherapy Market Size Share by Type (2021-2032) Figure 21. Latin America Cancer Radioimmunotherapy Market Size Share by Type (2021-2032) Figure 22. Middle East and Africa Cancer Radioimmunotherapy Market Size Share by Type (2021-2032) Figure 23. Solid Tumor Image Figure 24. Global Solid Tumor Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Non Hodgkin Lymphoma Image Figure 26. Global Non Hodgkin Lymphoma Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Global Cancer Radioimmunotherapy Market Size Overview by Application (2021-2032) & (US$ Million) Figure 28. Global Cancer Radioimmunotherapy Market Share by Application 2025 VS 2032 Figure 29. North America Cancer Radioimmunotherapy Market Size Share by Application (2021-2032) Figure 30. Europe Cancer Radioimmunotherapy Market Size Share by Application (2021-2032) Figure 31. Asia-Pacific Cancer Radioimmunotherapy Market Size Share by Application (2021-2032) Figure 32. Latin America Cancer Radioimmunotherapy Market Size Share by Application (2021-2032) Figure 33. Middle East and Africa Cancer Radioimmunotherapy Market Size Share by Application (2021-2032) Figure 34. Global Top 5 and 10 Cancer Radioimmunotherapy Players Market Share by Revenue in 2025 Figure 35. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 36. North America Cancer Radioimmunotherapy Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 37. North America Cancer Radioimmunotherapy Market Share by Country: 2021 VS 2025 VS 2032 Figure 38. North America Cancer Radioimmunotherapy Market Share by Country (2021-2032) Figure 39. Europe Cancer Radioimmunotherapy Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 40. Europe Cancer Radioimmunotherapy Market Share by Country: 2021 VS 2025 VS 2032 Figure 41. Europe Cancer Radioimmunotherapy Market Share by Country (2021-2032) Figure 42. Asia-Pacific Cancer Radioimmunotherapy Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 43. Asia-Pacific Cancer Radioimmunotherapy Market Share by Country: 2021 VS 2025 VS 2032 Figure 44. Asia-Pacific Cancer Radioimmunotherapy Market Share by Country (2021-2032) Figure 45. Latin America Cancer Radioimmunotherapy Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Latin America Cancer Radioimmunotherapy Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Latin America Cancer Radioimmunotherapy Market Share by Country (2021-2032) Figure 48. Middle East & Africa Cancer Radioimmunotherapy Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 49. Middle East & Africa Cancer Radioimmunotherapy Market Share by Country: 2021 VS 2025 VS 2032 Figure 50. Middle East & Africa Cancer Radioimmunotherapy Market Share by Country (2021-2032) Figure 51. Years Considered Figure 52. Research Process Figure 53. Key Executives Interviewed

Scope & coverage.

Types
  • Beta-emitting
  • Targeted Alpha Therapy
Applications
  • Solid Tumor
  • Non Hodgkin Lymphoma
Companies covered
  • Novartis
  • Bayer
  • Y-mAbs Therapeutics
  • Telix Pharmaceuticals
  • RadioMedix
  • Philogen
  • Orano Med
  • Nordic Nanovector
  • Mundipharma
  • Lantheus
  • Gilead Sciences
  • Fusion Pharmaceuticals
  • Curium Pharmaceuticals
  • Curasight
  • Clarity Pharmaceuticals
  • China Isotope & Radiation
  • Aurobindo Pharma
  • Actinium Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Cancer Radioimmunotherapy Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Cancer Radioimmunotherapy Market Size by Region (2021-2032)
  5. 1.4.1 Global Cancer Radioimmunotherapy Market Size by Region (2021-2026)
  6. 1.4.2 Global Cancer Radioimmunotherapy Market Size by Region (2027-2032)
  7. 1.5 Key Regions Cancer Radioimmunotherapy Market Size (2021-2032)
  8. 1.5.1 North America Cancer Radioimmunotherapy Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Cancer Radioimmunotherapy Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Cancer Radioimmunotherapy Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Cancer Radioimmunotherapy Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Cancer Radioimmunotherapy Market Size Growth Rate (2021-2032)
2 Cancer Radioimmunotherapy Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Beta-emitting
  3. 2.1.2 Targeted Alpha Therapy
  4. 2.2 Global Cancer Radioimmunotherapy Market Size by Type
  5. 2.2.1 Global Cancer Radioimmunotherapy Market Size Overview by Type (2021-2032)
  6. 2.2.2 Global Cancer Radioimmunotherapy Historic Market Size Review by Type (2021-2026)
  7. 2.2.3 Global Cancer Radioimmunotherapy Market Size Forecasted by Type (2027-2032)
  8. 2.3 Global Cancer Radioimmunotherapy Market Size by Regions
  9. 2.3.1 North America Cancer Radioimmunotherapy Market Size Breakdown by Type (2021-2026)
  10. 2.3.2 Europe Cancer Radioimmunotherapy Market Size Breakdown by Type (2021-2026)
  11. 2.3.3 Asia-Pacific Cancer Radioimmunotherapy Market Size Breakdown by Type (2021-2026)
  12. 2.3.4 South America Cancer Radioimmunotherapy Market Size Breakdown by Type (2021-2026)
  13. 2.3.5 Middle East and Africa Cancer Radioimmunotherapy Market Size Breakdown by Type (2021-2026)
3 Cancer Radioimmunotherapy Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Solid Tumor
  3. 3.1.2 Non Hodgkin Lymphoma
  4. 3.2 Global Cancer Radioimmunotherapy Market Size by Application
  5. 3.2.1 Global Cancer Radioimmunotherapy Market Size Overview by Application (2021-2032)
  6. 3.2.2 Global Cancer Radioimmunotherapy Historic Market Size Review by Application (2021-2026)
  7. 3.2.3 Global Cancer Radioimmunotherapy Market Size Forecasted by Application (2027-2032)
  8. 3.3 Global Cancer Radioimmunotherapy Market Size by Regions
  9. 3.3.1 North America Cancer Radioimmunotherapy Market Size Breakdown by Application (2021-2026)
  10. 3.3.2 Europe Cancer Radioimmunotherapy Market Size Breakdown by Application (2021-2026)
  11. 3.3.3 Asia-Pacific Cancer Radioimmunotherapy Market Size Breakdown by Application (2021-2026)
  12. 3.3.4 South America Cancer Radioimmunotherapy Market Size Breakdown by Application (2021-2026)
  13. 3.3.5 Middle East and Africa Cancer Radioimmunotherapy Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Cancer Radioimmunotherapy Industry Trends
  2. 4.2 Cancer Radioimmunotherapy Industry Drivers
  3. 4.3 Cancer Radioimmunotherapy Industry Opportunities and Challenges
  4. 4.4 Cancer Radioimmunotherapy Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Cancer Radioimmunotherapy Revenue (2021-2026)
  2. 5.2 Global Cancer Radioimmunotherapy Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Cancer Radioimmunotherapy Key Company Headquarters & Area Served
  4. 5.4 Global Cancer Radioimmunotherapy Company, Product Type & Application
  5. 5.5 Global Cancer Radioimmunotherapy Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Cancer Radioimmunotherapy Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Cancer Radioimmunotherapy Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Cancer Radioimmunotherapy Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Novartis
  2. 6.1.1 Novartis Company Information
  3. 6.1.2 Novartis Business Overview
  4. 6.1.3 Novartis Cancer Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Novartis Cancer Radioimmunotherapy Product Portfolio
  6. 6.1.5 Novartis Recent Developments
  7. 6.2 Bayer
  8. 6.2.1 Bayer Company Information
  9. 6.2.2 Bayer Business Overview
  10. 6.2.3 Bayer Cancer Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Bayer Cancer Radioimmunotherapy Product Portfolio
  12. 6.2.5 Bayer Recent Developments
  13. 6.3 Y-mAbs Therapeutics
  14. 6.3.1 Y-mAbs Therapeutics Company Information
  15. 6.3.2 Y-mAbs Therapeutics Business Overview
  16. 6.3.3 Y-mAbs Therapeutics Cancer Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Y-mAbs Therapeutics Cancer Radioimmunotherapy Product Portfolio
  18. 6.3.5 Y-mAbs Therapeutics Recent Developments
  19. 6.4 Telix Pharmaceuticals
  20. 6.4.1 Telix Pharmaceuticals Company Information
  21. 6.4.2 Telix Pharmaceuticals Business Overview
  22. 6.4.3 Telix Pharmaceuticals Cancer Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Telix Pharmaceuticals Cancer Radioimmunotherapy Product Portfolio
  24. 6.4.5 Telix Pharmaceuticals Recent Developments
  25. 6.5 RadioMedix
  26. 6.5.1 RadioMedix Company Information
  27. 6.5.2 RadioMedix Business Overview
  28. 6.5.3 RadioMedix Cancer Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 RadioMedix Cancer Radioimmunotherapy Product Portfolio
  30. 6.5.5 RadioMedix Recent Developments
  31. 6.6 Philogen
  32. 6.6.1 Philogen Company Information
  33. 6.6.2 Philogen Business Overview
  34. 6.6.3 Philogen Cancer Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Philogen Cancer Radioimmunotherapy Product Portfolio
  36. 6.6.5 Philogen Recent Developments
  37. 6.7 Orano Med
  38. 6.7.1 Orano Med Company Information
  39. 6.7.2 Orano Med Business Overview
  40. 6.7.3 Orano Med Cancer Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Orano Med Cancer Radioimmunotherapy Product Portfolio
  42. 6.7.5 Orano Med Recent Developments
  43. 6.8 Nordic Nanovector
  44. 6.8.1 Nordic Nanovector Company Information
  45. 6.8.2 Nordic Nanovector Business Overview
  46. 6.8.3 Nordic Nanovector Cancer Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Nordic Nanovector Cancer Radioimmunotherapy Product Portfolio
  48. 6.8.5 Nordic Nanovector Recent Developments
  49. 6.9 Mundipharma
  50. 6.9.1 Mundipharma Company Information
  51. 6.9.2 Mundipharma Business Overview
  52. 6.9.3 Mundipharma Cancer Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Mundipharma Cancer Radioimmunotherapy Product Portfolio
  54. 6.9.5 Mundipharma Recent Developments
  55. 6.10 Lantheus
  56. 6.10.1 Lantheus Company Information
  57. 6.10.2 Lantheus Business Overview
  58. 6.10.3 Lantheus Cancer Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Lantheus Cancer Radioimmunotherapy Product Portfolio
  60. 6.10.5 Lantheus Recent Developments
  61. 6.11 Gilead Sciences
  62. 6.11.1 Gilead Sciences Company Information
  63. 6.11.2 Gilead Sciences Business Overview
  64. 6.11.3 Gilead Sciences Cancer Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Gilead Sciences Cancer Radioimmunotherapy Product Portfolio
  66. 6.11.5 Gilead Sciences Recent Developments
  67. 6.12 Fusion Pharmaceuticals
  68. 6.12.1 Fusion Pharmaceuticals Company Information
  69. 6.12.2 Fusion Pharmaceuticals Business Overview
  70. 6.12.3 Fusion Pharmaceuticals Cancer Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Fusion Pharmaceuticals Cancer Radioimmunotherapy Product Portfolio
  72. 6.12.5 Fusion Pharmaceuticals Recent Developments
  73. 6.13 Curium Pharmaceuticals
  74. 6.13.1 Curium Pharmaceuticals Company Information
  75. 6.13.2 Curium Pharmaceuticals Business Overview
  76. 6.13.3 Curium Pharmaceuticals Cancer Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Curium Pharmaceuticals Cancer Radioimmunotherapy Product Portfolio
  78. 6.13.5 Curium Pharmaceuticals Recent Developments
  79. 6.14 Curasight
  80. 6.14.1 Curasight Company Information
  81. 6.14.2 Curasight Business Overview
  82. 6.14.3 Curasight Cancer Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Curasight Cancer Radioimmunotherapy Product Portfolio
  84. 6.14.5 Curasight Recent Developments
  85. 6.15 Clarity Pharmaceuticals
  86. 6.15.1 Clarity Pharmaceuticals Company Information
  87. 6.15.2 Clarity Pharmaceuticals Business Overview
  88. 6.15.3 Clarity Pharmaceuticals Cancer Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 Clarity Pharmaceuticals Cancer Radioimmunotherapy Product Portfolio
  90. 6.15.5 Clarity Pharmaceuticals Recent Developments
  91. 6.16 China Isotope & Radiation
  92. 6.16.1 China Isotope & Radiation Company Information
  93. 6.16.2 China Isotope & Radiation Business Overview
  94. 6.16.3 China Isotope & Radiation Cancer Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 China Isotope & Radiation Cancer Radioimmunotherapy Product Portfolio
  96. 6.16.5 China Isotope & Radiation Recent Developments
  97. 6.17 Aurobindo Pharma
  98. 6.17.1 Aurobindo Pharma Company Information
  99. 6.17.2 Aurobindo Pharma Business Overview
  100. 6.17.3 Aurobindo Pharma Cancer Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 Aurobindo Pharma Cancer Radioimmunotherapy Product Portfolio
  102. 6.17.5 Aurobindo Pharma Recent Developments
  103. 6.18 Actinium Pharmaceuticals
  104. 6.18.1 Actinium Pharmaceuticals Company Information
  105. 6.18.2 Actinium Pharmaceuticals Business Overview
  106. 6.18.3 Actinium Pharmaceuticals Cancer Radioimmunotherapy Revenue, Global Share and Gross Margin (2021-2026)
  107. 6.18.4 Actinium Pharmaceuticals Cancer Radioimmunotherapy Product Portfolio
  108. 6.18.5 Actinium Pharmaceuticals Recent Developments
7 North America
  1. 7.1 North America Cancer Radioimmunotherapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Cancer Radioimmunotherapy Market Size by Country (2021-2026)
  3. 7.3 North America Cancer Radioimmunotherapy Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Cancer Radioimmunotherapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Cancer Radioimmunotherapy Market Size by Country (2021-2026)
  3. 8.3 Europe Cancer Radioimmunotherapy Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Cancer Radioimmunotherapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Cancer Radioimmunotherapy Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Cancer Radioimmunotherapy Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Cancer Radioimmunotherapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Cancer Radioimmunotherapy Market Size by Country (2021-2026)
  3. 10.3 South America Cancer Radioimmunotherapy Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Cancer Radioimmunotherapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Cancer Radioimmunotherapy Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Cancer Radioimmunotherapy Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst